MOTS-c: A Tiny 16-Amino-Acid Peptide from Mitochondria That Could Treat Diabetes, Obesity, and Aging

MOTS-c is encoded by the 12S rRNA region of the mitochondrial genome and is expressed across multiple tissues and found in blood plasma. Key properties: translocates from mitochondria to the nucleus during metabolic stress to regulate gene expression, improves glucose metabolism in skeletal muscle, plasma levels decrease with age, and demonstrates benefits in preclinical models of diabetes, obesity, insulin resistance, cardiovascular disease, inflammation, and aging. The review also discusses synthetic biology approaches for MOTS-c production and delivery.

Narrative review of the published literature on MOTS-c, covering its discovery, molecular mechanisms (mitochondrial-to-nuclear translocation, gene regulation), physiological functions, disease applications, and potential therapeutic development strategies including synthetic biology approaches.

MOTS-c represents a paradigm shift in peptide biology — the idea that mitochondria communicate with the nucleus through peptide signals was revolutionary when discovered. The fact that MOTS-c levels decline with age and that supplementing it can improve metabolic function suggests it could address the root metabolic dysfunction underlying multiple age-related diseases simultaneously. Rather than treating diabetes, obesity, and cardiovascular disease separately, MOTS-c targets the underlying mitochondrial-metabolic axis.

Mitochondrial-derived peptides (MDPs) including MOTS-c, humanin, and SHLP1-6 are an entirely new class of signaling molecules discovered within the last decade. They challenge the long-held view that mitochondria are passive organelles — instead, they actively signal to the rest of the cell and body through peptides. MOTS-c is particularly exciting because it directly links mitochondrial function to nuclear gene regulation, providing a molecular explanation for how mitochondrial decline drives aging and metabolic disease.

Most evidence for MOTS-c's therapeutic potential comes from preclinical studies (cell culture and animal models). No clinical trials have been reported. The mechanisms by which MOTS-c enters the nucleus and regulates gene expression are not fully characterized. How MOTS-c is released from mitochondria into the bloodstream (where it's detectable as a circulating peptide) is unclear. Manufacturing challenges for a 16-amino-acid mitochondrial peptide are acknowledged but not solved. The decline in MOTS-c with age is documented but whether supplementation can reverse age-related metabolic decline in humans is unknown.